Cited 43 times in
Drug-eluting stent in malignant biliary obstruction.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이동기 | - |
dc.date.accessioned | 2015-04-24T16:47:10Z | - |
dc.date.available | 2015-04-24T16:47:10Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 1868-6974 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/104167 | - |
dc.description.abstract | INTRODUCTION: In unresectable malignant bile duct obstruction, endoscopic stent insertion is the treatment of choice. However, the current stent allows only mechanical palliation of the obstruction, and has no anti-tumor effect. Currently, in the vascular field, the drug-eluting stent (DES) is very highly favored. MATERIAL AND METHODS: The requirements for a DES in a non-vascular tract, such as the bile duct, are far different from those of a DES to be used in the vascular tract. The non-vascular DES must suppress tumor proliferation as well as mucosal hyperplasia. For example, the non-vascular stent might be covered with a membrane that gradually releases a chemo-agent. We do not have much experience with DES in the bile duct. Nonetheless, we are continuously testing many anti-tumor agents in animal and human studies. CONCLUSION: We expect and hope DES will work effectively for tumor cells in diverse ways and, more importantly, will prolong stent patency and the patients' survival periods. But considerable investigation and a clinical study of DES will be required to achieve these goals. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 628~632 | - |
dc.relation.isPartOf | JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use | - |
dc.subject.MESH | Bile Duct Neoplasms/complications | - |
dc.subject.MESH | Bile Duct Neoplasms/diagnosis | - |
dc.subject.MESH | Bile Duct Neoplasms/therapy* | - |
dc.subject.MESH | Catheterization/instrumentation | - |
dc.subject.MESH | Cholestasis/etiology | - |
dc.subject.MESH | Cholestasis/pathology* | - |
dc.subject.MESH | Cholestasis/therapy* | - |
dc.subject.MESH | Drug-Eluting Stents* | - |
dc.subject.MESH | Endoscopy, Digestive System/methods | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Risk Assessment | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Drug-eluting stent in malignant biliary obstruction. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Dong Ki Lee | - |
dc.identifier.doi | 10.1007/s00534-009-0135-1 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02723 | - |
dc.relation.journalcode | J01440 | - |
dc.identifier.eissn | 1868-6982 | - |
dc.identifier.pmid | 19554255 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs00534-009-0135-1 | - |
dc.subject.keyword | Drug-eluting stent | - |
dc.subject.keyword | Malignant biliary obstruction | - |
dc.subject.keyword | Cholangiocarcinoma | - |
dc.contributor.alternativeName | Lee, Dong Ki | - |
dc.contributor.affiliatedAuthor | Lee, Dong Ki | - |
dc.citation.volume | 16 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 628 | - |
dc.citation.endPage | 632 | - |
dc.identifier.bibliographicCitation | JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, Vol.16(5) : 628-632, 2009 | - |
dc.identifier.rimsid | 54586 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.